- The final results of the APLICOV-PC study (Phase I-II), which were initially released last May and which the Company shared with the scientific community, demonstrate the safety of plitidepsin's use in patients with COVID-19 and postulate a positive therapeutic impact on the evolution of the disease.
- PharmaMar confirms in vitro activity of plitidepsin against several variants, including Delta and Omicron.
- The Life Science Alliance journal is co-founded by the Rockefeller University, the European Molecular Biology Organization (EMBO) and Cold Spring Harbor Laboratory.
PR Newswire
MADRID, Jan. 11, 2022